Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denileukin Diftitox in Metastatic Melanoma or Kidney Cancer
NCT00082914Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2004
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of denileukin diftitox in melanoma and kidney cancer (2 arms), sponsored by National Cancer Institute. Primary endpoint: Clinical Response. Started Mar 2004; status: completed.
02
Drugs
denileukin diftitox
03
Conditions
melanomakidney cancer
Beyond the preview
Go deeper on NCT00082914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082914.